Results 301 to 310 of about 365,960 (349)
Some of the next articles are maybe not open access.
Degludec: A Novel Basal Insulin
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2012Limitations of conventional human basal insulins like NPH have led to the development of more stable and peak less analogs. However, the first generation of basal analogs like glargine and detemir has certain shortcomings which do not allow them to be termed ideal basal insulin. Degludec, a novel basal insulin analog has the potential to overcome these
Sanjay, Kalra +2 more
openaire +3 more sources
Insulin degludec – a new-generation basal insulin
Expert Opinion on Biological Therapy, 2012Insulin degludec may provide dosing options for patients who, because of their lifestyle, require some flexibility in adhering to an insulin regimen, and it may also reduce the risk of hypoglycemia compared with the basal insulins that are currently available.
Ammar, Wakil, Stephen L, Atkin
openaire +2 more sources
Insulin detemir: a new basal insulin analogue
Diabetes, Obesity and Metabolism, 2005Basal insulin therapy is an integral part of the intensive management of type 1 diabetes and it is also often used in type 2 diabetes. An ideal insulin regimen in patients with diabetes would mirror the 24‐h insulin profile of a non‐diabetic person, thereby preventing hyperglycaemia without inducing hypoglycaemia.
Handrean, Soran, Naveed, Younis
openaire +2 more sources
The Lancet, 1968
Abstract Glucose intolerance, resistance to ketosis, and hypertriglyceridaemia are among the many metabolic disturbances which have been associated with obesity. Recent investigations have provided new insights into this puzzling condition, and suggest that several of these apparently unrelated abnormalities may be closely related to the effects of ...
openaire +3 more sources
Abstract Glucose intolerance, resistance to ketosis, and hypertriglyceridaemia are among the many metabolic disturbances which have been associated with obesity. Recent investigations have provided new insights into this puzzling condition, and suggest that several of these apparently unrelated abnormalities may be closely related to the effects of ...
openaire +3 more sources
Insulin Degludec: A Novel Basal Insulin Analogue
Annals of Pharmacotherapy, 2013OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical trial data, adverse effects, and potential role in therapy of insulin degludec. DATA SOURCES: Articles were identified using the MEDLINE database (January 1996-December 2012). Abstracts and posters were identified from respective congressional websites and published supplements of the ...
Jennifer D, Goldman-Levine +2 more
openaire +2 more sources
Insulin Detemir—A New Basal Insulin Analog
Annals of Pharmacotherapy, 2005OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical trial data, adverse effects, and role in therapy of insulin detemir. DATA SOURCES: Articles and meeting abstracts were identified through searches of MEDLINE (1996–June 2004), EMBASE (1980–June 2004), and International Pharmaceutical Abstracts (1970–June 2004) databases, and unpublished ...
Jennifer D, Goldman-Levine, Karen W, Lee
openaire +2 more sources
Insulin Detemir and Basal Insulin Therapy
Endocrinology and Metabolism Clinics of North America, 2007With the introduction of insulin detemir (Levemir [Novo Nordisk A/S, Bagsvaerd, Denmark]), a long-acting basal insulin analog, it is an opportune moment to reevaluate the use of basal insulin therapy and consider current treatment strategies, including the use of insulin detemir.
openaire +2 more sources
Diabetes Technology & Therapeutics, 2013
Diabetes has been known to mankind for hundreds of years and was considered a deadly disease before the advent of insulin. It was the discovery of insulin by Frederick Banting and Charles Best that revolutionized the management of diabetes. Early insulins were made from either bovine or porcine whole pancreata.
Viral N, Shah +4 more
openaire +2 more sources
Diabetes has been known to mankind for hundreds of years and was considered a deadly disease before the advent of insulin. It was the discovery of insulin by Frederick Banting and Charles Best that revolutionized the management of diabetes. Early insulins were made from either bovine or porcine whole pancreata.
Viral N, Shah +4 more
openaire +2 more sources
Basal Insulin: Beyond Glycemia
Postgraduate Medicine, 2011Insulin is a pleiotropic hormone with numerous effects at the cellular, tissue, and organismal levels. Clinicians are familiar with physiological effects of insulin on carbohydrate metabolism, including stimulation of glucose uptake in skeletal muscle and the suppression of glucose production from the liver.
openaire +2 more sources
The Future of Basal Insulin Supplementation
Diabetes Technology & Therapeutics, 2011This review presents an overview of the candidates for an improved basal insulin in the pharmaceutical pipeline. The first new basal insulin to enter the market is most likely insulin degludec (IDeg), currently reporting in phase 3 of development, from Novo Nordisk (Bagsvaerd, Denmark).
Simon, Airin C. R., DeVries, J. Hans
openaire +2 more sources